Category: Takeda

Top antibody-drug conjugate (ADC) companies leading the industry

The antibody-drug conjugate (ADC) field is witnessing an expansion in the variety of conjugation techniques, linker chemistry, and payloads being used, moving beyond traditional tubulin inhibitors to include novel mechanisms of action. Investments in ADC research continue to grow, with significant funding rounds and acquisitions. For example, Novo Holdings’ $105…

Continue Reading Top antibody-drug conjugate (ADC) companies leading the industry

Computational Biology, Bioinformatics Internship – Summer 2024 at Takeda Pharmaceutical

By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that the information I provide in my application will be processed in line with Takeda’sPrivacy Noticeand Terms of Use. I further attest that all information I submit in my employment application is true…

Continue Reading Computational Biology, Bioinformatics Internship – Summer 2024 at Takeda Pharmaceutical

Growth Is Still a Better Choice

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is a leader in the global cystic fibrosis therapeutics market. In addition, the company has an extensive portfolio of experimental medicines aimed at treating common diseases such as type 1 diabetes, sickle cell anemia and APOL1-mediated kidney disease (AMKD). Investment thesis On Dec. 8, the Food…

Continue Reading Growth Is Still a Better Choice

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

Abstract Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13…

Continue Reading Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

Reproxalap in Patients with Seasonal Allergic Conjunctivitis

Introduction Reproxalap, a novel chemical entity in late-stage clinical development for the treatment of ocular inflammation, chemically sequesters a class of small molecules known as reactive aldehyde species (RASP). Via covalent binding to amine and thiol residues, RASP modulate the structure and function of proteins in an analog manner1 depending…

Continue Reading Reproxalap in Patients with Seasonal Allergic Conjunctivitis

Japan Epigenetics Market Outlook, Size, Segmentation Analysis, Share, Drivers and Forecast 2032 | Taiwan News

At Report Ocean, our goal is to merge comprehensive industry insights with top-notch research methodologies, empowering our clients to conquer future business challenges and attain their goals. Our services are meticulously crafted to align with market dynamics. The Japan epigenetics market held a market value of USD 22.4 million in…

Continue Reading Japan Epigenetics Market Outlook, Size, Segmentation Analysis, Share, Drivers and Forecast 2032 | Taiwan News

Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

“It’s hoped that [longer persistence with oral DEC-C] would translate to better outcomes because those patients are able to stay on a treatment that takes time to work,” said Amer Zeidan, MD, in a presentation during the meeting. Retrospective, real-world results showed that oral decitabine and cedazuridine (DEC-C) and standard…

Continue Reading Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

The mRNA shield against dengue

Swetha Raghavan from the Dengue Vaccine Programme at the National Centre for Biological Sciences (NCBS), said: “Our attempt is a first mRNA dengue vaccine for India as an alternative to traditional approaches. One can choose specific antigenic regions to overcome the challenges of Antibody-Dependent Enhancement, confer protection across multiple serotypes,…

Continue Reading The mRNA shield against dengue

tRNA therapeutics for genetic diseases

Huang, X. et al. The landscape of mRNA nanomedicine. Nat. Med. 28, 2273–2287 (2022). Article  CAS  Google Scholar  Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586–1600 (2022). Article  CAS  Google Scholar  Brown, A., Shao, S.,…

Continue Reading tRNA therapeutics for genetic diseases

Diffuse Large B-cell Lymphoma Market to Observe Impressive Growth Ubix Therapeutics, Otsuka Pharmaceutical, Biomea Fusion, Autolus Limited, Xynomic Pharmaceuticals companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the DLBCL, historical and forecasted epidemiology as well as the DLBCL market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. {Delhi, India} To strategically…

Continue Reading Diffuse Large B-cell Lymphoma Market to Observe Impressive Growth Ubix Therapeutics, Otsuka Pharmaceutical, Biomea Fusion, Autolus Limited, Xynomic Pharmaceuticals companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy | Molecular Cancer

Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019;20:377–88. Article  CAS  PubMed  PubMed Central  Google Scholar  Li L, Papadopoulos V. Advances in stem cell research for the treatment of primary hypogonadism. Nat Rev Urol. 2021;18:487–507. Article  CAS  PubMed  Google Scholar  Lawrence…

Continue Reading Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy | Molecular Cancer

Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

As per the report by Fortune Business Insights, The Biopharmaceuticals Market size is projected to reach USD 799.76 Billion by 2030, at a CAGR of 7.9% during the forecast period. Biopharmaceuticals Market Biopharmaceuticals Market (2023-2030) Pune, India, Nov. 27, 2023 (GLOBE NEWSWIRE) — The global biopharmaceuticals market size was USD…

Continue Reading Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

BCL-2-Like Protein Market Will Generate Record Revenue by 2029

BCL-2-Like Protein Market is anticipated to grow at a significant CAGR during the forecast period. BCL-2, also known as B Cell Lymphoma 2, is a protein encoding gene belonging to the B cell lymphoma family. The market growth is majorly attributable to the growth is the significant prevalence of diffuse…

Continue Reading BCL-2-Like Protein Market Will Generate Record Revenue by 2029

Phase 3 Trials Reveal New Standards of Care for NSCLC

Data from several recent phase 3 trials support changes to standard care for non-small cell lung cancer (NSCLC), according to researchers. Results from the MARIPOSA trial suggest that amivantamab plus lazertinib represents a new first-line standard of care for patients with advanced, EGFR-mutant NSCLC.1 The MARIPOSA-2 trial suggests that amivantamab…

Continue Reading Phase 3 Trials Reveal New Standards of Care for NSCLC

Phylogenetic, population structure, and population demographic analyses reveal that Vicia sepium in Japan is native and not introduced

Vicia sepium L. (bush vetch, Fabaceae) is a small perennial herb that is widely distributed on the Eurasian continent in the temperate Euro-Siberian broad-leaved forest region1. It has a wide distribution, both horizontally and vertically; for example, in the Swiss Alps, it grows from the lowlands to the sub alpine…

Continue Reading Phylogenetic, population structure, and population demographic analyses reveal that Vicia sepium in Japan is native and not introduced

Impact of AlphaFold on structure prediction of protein complexes: The CASP15-CAPRI experiment.

journal contribution posted on 2023-11-23, 11:51 authored by Marc F Lensink, Guillaume Brysbaert, Nessim Raouraoua, Paul A Bates, Marco Giulini, Rodrigo V Honorato, Charlotte van Noort, Joao MC Teixeira, Alexandre MJJ Bonvin, Ren Kong, Hang Shi, Xufeng Lu, Shan Chang, Jian Liu, Zhiye Guo, Xiao Chen, Alex Morehead, Raj S…

Continue Reading Impact of AlphaFold on structure prediction of protein complexes: The CASP15-CAPRI experiment.

The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

B-cell lymphoma, a subtype of non-Hodgkin lymphoma, stands as the leading cancer diagnosis in the United States, comprising 85% of all cases. This cancer targets the lymphatic system, encompassing lymph nodes, vessels, and related tissues responsible for fluid transportation within the body. The outlook for B-cell lymphoma patients has been…

Continue Reading The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

Researchers identify key factors involved in DNA repair mechanism

Researchers from Tokyo Metropolitan University have identified key factors in the mechanism behind DNA repair in our bodies. For the first time, they showed that the “proofreading” portion of the DNA replicating enzyme polymerase epsilon ensured safe termination of replication at damaged portions of the DNA strand, ultimately saving DNA…

Continue Reading Researchers identify key factors involved in DNA repair mechanism

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Competing interests JS reports a consulting role for AstraZeneca, Bayer, Kite and Sanofi, and institutional research funding from Ambrx, Arcus, Arvinas, BMS, Exelixis, Lilly, MacroGenics and Merck. SC reports consultancy to Astellas Pharma, Bayer, Beigene, Clovis, Janssen-Cilag, Johnson & Johnson, Novartis and Sanofi; research funding (self) from Clovis; and honoraria…

Continue Reading Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Abstract Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, open-label study…

Continue Reading Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

A tRNA-modifying enzyme facilitates RNase P activity in Arabidopsis nuclei

Chapeville, F. et al. On the role of soluble ribonucleic acid in coding for amino acids. Proc. Natl Acad. Sci. Usa. 48, 1086–1092 (1962). Article  CAS  PubMed  PubMed Central  Google Scholar  Korostelev, A., Trakhanov, S., Laurberg, M. & Noller, H. F. Crystal structure of a 70S ribosome–tRNA complex reveals functional…

Continue Reading A tRNA-modifying enzyme facilitates RNase P activity in Arabidopsis nuclei

FDA Approves Fruquintinib for Patients With Pretreated Metastatic Colorectal Cancer

FDA Approves Fruquintinib for Patients With Pretreated Metastatic Colorectal Cancer Fruquintinib (Fruzaqla), an oral therapy, is now approved to treat adults with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.1 The FDA approval…

Continue Reading FDA Approves Fruquintinib for Patients With Pretreated Metastatic Colorectal Cancer

Who are the leading innovators in TERT screening for the pharmaceutical industry?

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry. TERT screening is a key innovation area in genomics TERT gene promoter mutations lead to constitutive activation and expression….

Continue Reading Who are the leading innovators in TERT screening for the pharmaceutical industry?

Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

Oral and Poster Abstracts 652. Multiple Myeloma: Clinical and Epidemiological: Poster III Research, adult, Translational Research, assays, Plasma Cell Disorders, bioinformatics, Diseases, Lymphoid Malignancies, computational biology, Technology and Procedures, Study Population, Human, molecular testing, omics technologies Dor D. Abelman1,2, Jenna Eagles1*, Stephanie Pedersen1*,…

Continue Reading Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

BioTechX 2023: the highlights

BioTechX 2023, one of Europe’s largest conventions, that blends diagnostics, precision medicine and digital transformation in the field of healthcare, took place in the biotech hub of Basel, Switzerland. The event, which was held from October 4 to 6, hosted expert panelists who shared their knowledge on the digital transformation…

Continue Reading BioTechX 2023: the highlights

DNA damage response(DDR): a link between cellular senescence and human cytomegalovirus | Virology Journal

Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621. Article  CAS  PubMed  Google Scholar  Hayflick L. THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. Exp Cell Res. 1965;37:614–36. Article  CAS  PubMed  Google Scholar  Schmitt CA, Tchkonia T, Niedernhofer LJ, Robbins PD,…

Continue Reading DNA damage response(DDR): a link between cellular senescence and human cytomegalovirus | Virology Journal

Exploring Opportunities in the Bioinformatics

“Bioinformatics and Computational Biology Market “Worldwide Market Reports offers a UP-TO 70% discount on Bioinformatics and Computational Biology Market Reports on Single User Access and Unlimited User Access” The latest research study released by Worldwide Market Reports on “Bioinformatics and Computational Biology Market 2023 Forecast to 2030″ research provides accurate…

Continue Reading Exploring Opportunities in the Bioinformatics

Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

ALAMEDA, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients…

Continue Reading Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

September 2023 Recap: Drug Pipeline Updates

Drug Pharmacologic Class Proposed Indication Status Allergic Disorders Neffy (internal epinephrine; ARS Pharmaceuticals) Non-selective alpha and beta adrenergic agonist Treatment of severe allergic reactions, including anaphylaxis, for adults and children weighing at least 30kg. Complete Response Letter…

Continue Reading September 2023 Recap: Drug Pipeline Updates

RNA Targeting Small Molecule Drug Discovery Market Size, Share And Growth Analysis For 2023-2032

(MENAFN– EIN Presswire) RNA Targeting Small Molecule Drug Discovery Global Market Report 2023 – Market Size, Trends, And Market Forecast 2023-2032 The Business Research Company’s RNA Targeting Small Molecule Drug Discovery Global Market Report 2023 – Market Size, Trends, And Market Forecast 2023-2032 The Business Research Company’s global market reports…

Continue Reading RNA Targeting Small Molecule Drug Discovery Market Size, Share And Growth Analysis For 2023-2032

Takeda Announces Topline Results of Phase 3 ADMIRECD II Trial of Alofisel darvadstrocel in Complex Crohns Perianal Fistulas

Osaka, Japan & Cambridge, Mass., United States:   Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission…

Continue Reading Takeda Announces Topline Results of Phase 3 ADMIRECD II Trial of Alofisel darvadstrocel in Complex Crohns Perianal Fistulas

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel in Complex Crohn’s Perianal Fistulas -October 18, 2023 at 09:35 am EDT

OSAKA – Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data. The safety profile…

Continue Reading Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel in Complex Crohn’s Perianal Fistulas -October 18, 2023 at 09:35 am EDT

Takeda : Phase 3 Study Of Alofisel In Complex Crohn’s Perianal Fistulas Fails To Meet Main Goal

(RTTNews) – Takeda (TAK) said that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas, did not meet its primary endpoint of combined remission at 24 weeks. The safety profile for darvadstrocel was consistent with prior studies…

Continue Reading Takeda : Phase 3 Study Of Alofisel In Complex Crohn’s Perianal Fistulas Fails To Meet Main Goal

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study -October 17, 2023 at 07:30 pm EDT

Takeda Pharmaceutical Company Limited announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn?s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data. The safety profile for darvadstrocel…

Continue Reading Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study -October 17, 2023 at 07:30 pm EDT

Takeda Pharmaceutical (TAK) Reports Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel

Takeda (NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data. The safety profile for darvadstrocel…

Continue Reading Takeda Pharmaceutical (TAK) Reports Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel

Generation of quality-controled SARS-CoV-2 variant stocks

World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at covid19.who.int/ (2023). de Vries, M. et al. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19. J. Virol. 95, e01819-20 (2021). Article  PubMed  PubMed Central  Google Scholar  FDA. Emergency Use Authorization (Eua) of…

Continue Reading Generation of quality-controled SARS-CoV-2 variant stocks

Protein Engineering Market Size is Expanding at USD 15.25

Ottawa, Oct. 11, 2023 (GLOBE NEWSWIRE) — The global protein engineering market size is projected to hit around USD 15.25 billion by 2032. Advancements in protein engineering technology, including new gene editing tools like CRISPR-Cas9 and the development of novel computational algorithms, have opened new opportunities for protein design and…

Continue Reading Protein Engineering Market Size is Expanding at USD 15.25

Protein Engineering Market Size is Expanding at USD 15.25 Billion by 2032

Ottawa, Oct. 11, 2023 (GLOBE NEWSWIRE) — The global protein engineering market size is projected to hit around USD 15.25 billion by 2032. Advancements in protein engineering technology, including new gene editing tools like CRISPR-Cas9 and the development of novel computational algorithms, have opened new opportunities for protein design and…

Continue Reading Protein Engineering Market Size is Expanding at USD 15.25 Billion by 2032

The breakthrough in gene editing reveals the potential of Compact Enzyme as an effective treatment

A new CRISPR gene-editing tool, AsCas12f, has been developed and refined to be much more effective and compact than Cas9, which is widely used and could be used in genome-editing applications in humans. The AsCas12f enzyme, which is a CRISPR-based gene-editing tool, has been developed which is reminiscent of the…

Continue Reading The breakthrough in gene editing reveals the potential of Compact Enzyme as an effective treatment

ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

A 2020 Nature Cancer study found that patients with advanced non-small cell lung cancer (NSCLC) who had undetectable circulating tumor (ct)DNA after chemoradiotherapy “had excellent outcomes whether or not they received consolidation immune checkpoint inhibition (CICI) … the ctDNA response pattern early during CICI identified patients responding to consolidation therapy.”…

Continue Reading ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

Key Points Question  How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings  In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically…

Continue Reading Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

Compact Enzyme Promises More Effective Treatments

A new CRISPR gene-editing tool, AsCas12f, smaller than the commonly used Cas9, has been engineered for better efficiency and effectiveness in treating genetic disorders. Tested successfully in mice, this tool could lead to more compact and efficient genome-editing applications in humans. The newly designed CRISPR enzyme offers a more compact…

Continue Reading Compact Enzyme Promises More Effective Treatments

Japan firm Takeda’s dengue vaccine gets WHO panel backing, but no nod yet for phase 3 trials in India

New Delhi: A scientific advisory panel under the World Health Organization (WHO) has recommended a vaccine developed by Japanese pharma giant Takeda against dengue — a viral infection caused by the dengue virus (DENV), transmitted to humans through the bite of infected mosquitoes — for use in endemic countries. “The…

Continue Reading Japan firm Takeda’s dengue vaccine gets WHO panel backing, but no nod yet for phase 3 trials in India

Metastatic Prostate Cancer Market Size in the 7MM was ~USD 6400 million in 2022, Estimates DelveInsight

PRESS RELEASE Published October 3, 2023 “The Metastatic Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Metastatic Prostate Cancer pipeline products will significantly revolutionize the Metastatic Prostate Cancer market dynamics”   The Metastatic Prostate…

Continue Reading Metastatic Prostate Cancer Market Size in the 7MM was ~USD 6400 million in 2022, Estimates DelveInsight

Takeda Pharmaceutical to Withdraw Lung Cancer Drug Exkivity in US After Phase 3 Trial Fails; Shares Drop After Hours -October 02, 2023 at 05:11 pm EDT

Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows:…

Continue Reading Takeda Pharmaceutical to Withdraw Lung Cancer Drug Exkivity in US After Phase 3 Trial Fails; Shares Drop After Hours -October 02, 2023 at 05:11 pm EDT

Eosinophilic Esophagitis Pipeline, Clinical Trials, FDA Approvals and Emerging Drugs 2023 (Updated)

PRESS RELEASE Published September 30, 2023 DelveInsight’s, “Eosinophilic Esophagitis Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Eosinophilic Esophagitis pipeline landscape. It covers the Eosinophilic Esophagitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eosinophilic Esophagitis pipeline…

Continue Reading Eosinophilic Esophagitis Pipeline, Clinical Trials, FDA Approvals and Emerging Drugs 2023 (Updated)

Acute Graft-versus-Host Disease Pipeline, Clinical Trials, Emerging Therapies and FDA Approvals 2023 (Updated)

PRESS RELEASE Published September 27, 2023 DelveInsight’s, “Acute Graft-versus-Host Disease Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Acute Graft-versus-Host Disease pipeline landscape. It covers the Acute Graft-versus-Host Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the…

Continue Reading Acute Graft-versus-Host Disease Pipeline, Clinical Trials, Emerging Therapies and FDA Approvals 2023 (Updated)

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile consistent with prior vonoprazan studies New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for…

Continue Reading Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

Sickle Cell Disease Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated)

PRESS RELEASE Published September 22, 2023 DelveInsight’s, “Sickle Cell Disease Pipeline Insights 2023” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Sickle cell disease pipeline landscape. It covers the Sickle Cell Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the…

Continue Reading Sickle Cell Disease Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated)

Diffuse Large B-cell Lymphoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

PRESS RELEASE Published September 21, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Diffuse Large B-cell Lymphoma pipeline constitutes 80+ key companies continuously working towards developing 80+ Diffuse Large B-cell Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes…

Continue Reading Diffuse Large B-cell Lymphoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

Travere Therapeutics (TVTX) Reports Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) (“Travere”) today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) versus irbesartan. FILSPARI demonstrated long-term kidney function preservation and achieved a clinically…

Continue Reading Travere Therapeutics (TVTX) Reports Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI

Transcriptomics Meta-Analysis Reveals Phagosome and Innate Immune System Dysfunction as Potential Mechanisms in the Cortex of Alzheimer’s Disease Mouse Strains

Aken BL, Ayling S, Barrell D, Clarke L, Curwen V, Fairley S et al (2016) The Ensembl gene annotation system. Database (Oxford) baw093 Bagaria J, Nho K, An SSA (2021) Importance of GWAS in finding un-targeted genetic association of sporadic Alzheimer’s disease. Mol Cell Toxicol 17(3):233–244 Article  CAS  Google Scholar …

Continue Reading Transcriptomics Meta-Analysis Reveals Phagosome and Innate Immune System Dysfunction as Potential Mechanisms in the Cortex of Alzheimer’s Disease Mouse Strains

Diffuse Large B-cell Lymphoma Market to Show Immense Growth

New York, USA, Sept. 19, 2023 (GLOBE NEWSWIRE) — Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out – AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Takeda The DLBCL market has a diverse pipeline, with the emergence of…

Continue Reading Diffuse Large B-cell Lymphoma Market to Show Immense Growth

Extensive natural Agrobacterium-induced transformation in the genus Camellia

Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403–410. doi.org/10.1016/S0022-2836(05)80360-2 Article  CAS  PubMed  Google Scholar  Cai Y, Meng J, Cui Y, Tian M, Shi Z, Wang J (2022) Transcriptome and targeted hormone metabolome reveal the molecular mechanisms of flower…

Continue Reading Extensive natural Agrobacterium-induced transformation in the genus Camellia

Discover the synergy between biotech and medtech in Ghent

When you think about Ghent, Belgium, do you think about its historic city centre, with the Castle of the Counts and its intricate network of canals and waterways? Sure, but do you also think about how it’s poised to become the European technology capital? Mixing excellent infrastructure, talented individuals working…

Continue Reading Discover the synergy between biotech and medtech in Ghent

Phylotranscriptomics unveil a Paleoproterozoic-Mesoproterozoic origin and deep relationships of the Viridiplantae

Brocks, J. J. et al. The rise of algae in Cryogenian oceans and the emergence of animals. Nature 548, 578–581 (2017). Article  ADS  CAS  PubMed  Google Scholar  Leliaert, F. Green algae: Chlorophyta and Streptophyta. In Encyclopedia of microbiology 457–468 (Academic Press, 2019). Zhang, Z. et al. Origin and evolution of…

Continue Reading Phylotranscriptomics unveil a Paleoproterozoic-Mesoproterozoic origin and deep relationships of the Viridiplantae

For preventing HAE attacks, Takhzyro is better than Cinryze: Study

Takhzyro (lanadelumab) may be better than Cinryze at preventing swelling episodes in hereditary angioedema (HAE), according to a study based on data from Phase 3 clinical trials. The study, “Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study,” was published in Allergy. HAE is…

Continue Reading For preventing HAE attacks, Takhzyro is better than Cinryze: Study

The Top 25 Healthcare Technology Leaders of Houston for 2023

The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of Houston for 2023. Houston stands out as a prominent hub for medical device manufacturing, pharmaceuticals, and health research, boasting a thriving ecosystem encompassing over 1,100 well-established life sciences and biotechnology companies. These visionary-led enterprises are…

Continue Reading The Top 25 Healthcare Technology Leaders of Houston for 2023

A second update on mapping the human genetic architecture of COVID-19

Broad Institute of MIT and Harvard, Cambridge, MA, USA Masahiro Kanai, Christine Stevens, Benjamin M. Neale, Mark Daly, Andrea Ganna, Amy Trankiem, Mary K. Balaconis, Samuli Ripatti, Lindo Nkambul, Mark J. Daly, Sam Bryant & Matthew Solomonson University of California San Francisco, San Francisco, CA, USA Shea J. Andrews Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland Mattia Cordioli, Mark…

Continue Reading A second update on mapping the human genetic architecture of COVID-19

Meta-analysis of microarray and RNAseq data reveal OsbZIP52 to mediate salt stress responses in sensitive, tolerant and halophyte rice varieties | CABI Agriculture and Bioscience

Anon. Human Development Report 1997. 1997. Bailey TL, Johnson J, Grant CE, Noble WS. The MEME suite. Nucleic Acids Res. 2015;43(W1):W39-49. doi.org/10.1093/NAR/GKV416. Article  CAS  PubMed  PubMed Central  Google Scholar  Balchin D, Hayer-Hartl M, Hartl FU. In vivo aspects of protein folding and quality control. Science. 2016;353(6294):aac4354. doi.org/10.1126/science.aac4354. Article  CAS  PubMed …

Continue Reading Meta-analysis of microarray and RNAseq data reveal OsbZIP52 to mediate salt stress responses in sensitive, tolerant and halophyte rice varieties | CABI Agriculture and Bioscience

A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer

Background Effective treatment options are limited for patients (pts) with refractory metastatic colorectal cancer (mCRC). Fruquintinib (F), a highly selective, potent, oral tyrosine kinase inhibitor of VEGFR-1, -2, and -3, was approved in China in the 3L+ mCRC setting based on results from the FRESCO trial (NCT02314819). FRESCO-2 (NCT04322539) evaluated…

Continue Reading A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer

The global bone cancer treatment market size was valued at USD 2.1 billion in 2023 and is projected to reach USD 2.9 billion by 2030, exhibiting a CAGR of 5.2% from 2023 to 2030.

PRESS RELEASE Published August 25, 2023 List of reports available with us. Bone Cancer Treatment Market Size / CAGR / Sales Revenue   (Request Free Sample Report) Cervical Cancer Market Size / CAGR / Sales Revenue   (Request Free Sample Report) Cervical Cancer Vaccine Market Size / CAGR / Sales Revenue   (Request…

Continue Reading The global bone cancer treatment market size was valued at USD 2.1 billion in 2023 and is projected to reach USD 2.9 billion by 2030, exhibiting a CAGR of 5.2% from 2023 to 2030.

Translation dysregulation in neurodegenerative diseases: a focus on ALS | Molecular Neurodegeneration

Tandan R, Bradley WG. Amyotrophic lateral sclerosis: part 1. Clinical features, pathology, and ethical issues in management. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1985;18:271–80. Article  CAS  Google Scholar  Mehta P et al. Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016….

Continue Reading Translation dysregulation in neurodegenerative diseases: a focus on ALS | Molecular Neurodegeneration

CRISPR Approach to Induce Exon Skipping in Dystrophin Gene

A dual CRISPR-Cas3 system could be used to induce multi-exon skipping to restore the open reading frame of the dystrophin gene, a new study has found. Duchenne muscular dystrophy, a severe degenerative muscle disorder, is caused by mutations in the dystrophin gene that disrupt its open reading frame, leading to…

Continue Reading CRISPR Approach to Induce Exon Skipping in Dystrophin Gene

Diffuse Large B-cell Lymphoma (DLBCL) Pipeline Assessment,

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Diffuse Large B-cell Lymphoma pipeline constitutes 80+ key companies continuously working towards developing 80+ Diffuse Large B-cell Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. “Diffuse Large B-cell Lymphoma Pipeline…

Continue Reading Diffuse Large B-cell Lymphoma (DLBCL) Pipeline Assessment,

Wonder Drugs in the AI Age: The Asian Advantage

In 2018, long before the artificial intelligence (AI) bandwagon started careening down the mainstream, DeepMind, a subsidiary of Google parent Alphabet, developed a program named AlphaFold to predict protein structures faster and more accurately than biologists. Predicting protein shapes is a key aspect of drug development, disease treatment, and treatment…

Continue Reading Wonder Drugs in the AI Age: The Asian Advantage

Exelixis and Ipsen Announce Positive Results from Phase 3

– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer  – A trend toward improvement in overall survival was observed at first interim analysis  – Findings will…

Continue Reading Exelixis and Ipsen Announce Positive Results from Phase 3

Identification of two novel variants of the DMD gene

Introduction Duchenne muscular dystrophy (DMD, OMIM#310200) is a severe X-linked recessive, inherited neuromuscular disorder, characterized by rapidly progressive muscle weakness and muscle wasting throughout the body.1 DMD is more common in males than females, with an incidence rate of 1:5000 and 1:50,000,000, respectively.2 Female heterozygotes theoretically have 50% normal cells…

Continue Reading Identification of two novel variants of the DMD gene

Seagen Inc Announces Successful Phase 3 Trial for HER2Positive Metastatic Breast Cancer Treatment

Seagen Inc. has recently announced a groundbreaking development in the fight against HER2-positive metastatic breast cancer. The Phase 3 HER2CLIMB-02 clinical trial, conducted globally and across multiple centers, has successfully met its primary objective of progression-free survival (PFS) in patients who have previously received treatment for this aggressive form of…

Continue Reading Seagen Inc Announces Successful Phase 3 Trial for HER2Positive Metastatic Breast Cancer Treatment

How to make the leap into industry after a PhD

Plant physiologist Melanie Zeppel had heard that hard work, a good publication list and securing highly competitive postdoctoral research fellowships would guarantee a successful career in academia. Despite having it all, a faculty position eluded her for 12 years after her PhD. Frustrated with the wait, Zeppel, who is in…

Continue Reading How to make the leap into industry after a PhD

Specific detection of tau seeding activity in Alzheimer’s disease using rationally designed biosensor cells | Molecular Neurodegeneration

Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E, Mandelkow EM. Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J. 2013;32:2920–37. Article  CAS  PubMed  PubMed Central  Google Scholar  Li C, Gotz J. Somatodendritic accumulation of Tau in Alzheimer’s disease is promoted…

Continue Reading Specific detection of tau seeding activity in Alzheimer’s disease using rationally designed biosensor cells | Molecular Neurodegeneration

Profile of relugolix | DDDT

Introduction Prostate cancer remains one of the most commonly diagnosed malignancies among men.1,2 Moreover, the number of cancer-related deaths throughout the world has increased from 307,500 in 20121 to 375,304 in 2020.2 Although definitive therapy, such as radical prostatectomy and irradiation, offers excellent oncologic outcomes in most men with localized…

Continue Reading Profile of relugolix | DDDT

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

NEW YORK and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of Beth-Anne Lang, as Senior Vice President, Regulatory Affairs. Ms. Lang has more than 20 years of experience in…

Continue Reading Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum

-Record Net Product Sales of $544 Million in 2Q23, an Increase of 26% Over 2Q22, Contributing to Total Revenues of $604 Million in 2Q23- -Strong PADCEV® Growth Driven By Combination First-Line Advanced Urothelial Cancer Launch; Record ADCETRIS® Performance with Overall Survival Benefit Demonstrated in the ECHELON-1 Trial Added to Label-…

Continue Reading Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum

Activation of cell-free mtDNA-TLR9 signaling mediates chronic stress-induced social behavior deficits

Mahan AL, Ressler KJ. Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder. Trends Neurosci. 2012;35:24–35. Article  CAS  PubMed  Google Scholar  Koenigs M, Grafman J. Posttraumatic stress disorder: the role of medial prefrontal cortex and amygdala. Neuroscientist. 2009;15:540–8. Article  PubMed  PubMed Central  Google Scholar  Nemeroff CB, Vale…

Continue Reading Activation of cell-free mtDNA-TLR9 signaling mediates chronic stress-induced social behavior deficits

Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update

– Total Revenues of $469.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $409.6 million – – GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.31 – – Conference Call and Webcast Today at 5:00 PM Eastern Time – ALAMEDA, Calif., August 01, 2023–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today…

Continue Reading Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

Ovid Therapeutics Inc. NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference…

Continue Reading Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials | News

SAN DIEGO–(BUSINESS WIRE)–Jul 27, 2023– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its collaborator Merck, known as MSD outside of the United States and Canada, today announced positive topline results from two Phase 3 trials evaluating V116, an investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve and previously vaccinated individuals. If…

Continue Reading Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials | News

Medicxi announces $400M fund for life science companies

Medicxi, a European life sciences investment firm, has launched its $400 million Medicxi IV fund. The new fund will support companies with clear product visions to deliver transformative therapies for patients. Medicxi’s investments have resulted in the development of several marketed and late-stage development drugs, including Daratumumab (Genmab/Johnson & Johnson),…

Continue Reading Medicxi announces $400M fund for life science companies

Partial thyroid hormone-binding globulin deficiency

Introduction Thyroxine-binding globulin (TBG) is the main binding protein of the thyroid hormone in the human body. It combines around 75% of thyroxine (T4) and 70% of triiodofoxygen (T3).1 Thyroxine-binding globulin deficiency is a rare thyroid disease, mostly caused by a gene mutation, and is generally acquired through X-linked recessive…

Continue Reading Partial thyroid hormone-binding globulin deficiency

Crescendo Biologics raises $32M and expands cancer trial

Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has announced that it plans to augment the ongoing phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort.  Additional financing of $32 million has been secured with…

Continue Reading Crescendo Biologics raises $32M and expands cancer trial

Diffuse Large B-cell Lymphoma (DLBCL) Market Report 2032:

Diffuse Large B-cell Lymphoma (DLBCL) Market (New York, USA) DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diffuse Large B-cell Lymphoma (DLBCL), historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma (DLBCL) market trends in the United…

Continue Reading Diffuse Large B-cell Lymphoma (DLBCL) Market Report 2032:

Stem Cell Therapy Market Worth $6.20 Billion, Globally, by 2028 at 18.2% CAGR Lead by Allogenic Segment

PRESS RELEASE Published July 21, 2023 According to The Insight Partners, “Stem Cell Therapy Market Size, Share, Growth and Global Forecasts to 2028 – COVID-19 Impact and Global Analysis By Type (Adult Stem Cell Therapy, Embryonic Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, and Other Stem Cell Therapy), Treatment…

Continue Reading Stem Cell Therapy Market Worth $6.20 Billion, Globally, by 2028 at 18.2% CAGR Lead by Allogenic Segment

ctDNA negative status contributes to positive outcomes for DLBCL

Source/Disclosures Published by: Source: Herrera, A, et al. Abstract 7523. Presented at: American Society of Clinical Oncology Meeting; June 2-6, 2023; Chicago. Disclosures: Herrera reports consulting and funding from Abbvie, ADC Therapeutics, Adicet Bio, AstraZeneca/MedImmune, Bristol-Myers Squibb, Caribou Biosciences, Genentech/Roche, Genmab, Gilead Sciences, Karyopharm Therapeutics, Kite, a…

Continue Reading ctDNA negative status contributes to positive outcomes for DLBCL

Endometrial cancer drug gets breakthrough therapy designation

A study for potential registration of this combination in patients with previously treated advanced EMC in China has recently completed enrollment. It is a multi-center, open-label clinical study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab. Entry criteria include those EMC patients who experienced disease recurrence,…

Continue Reading Endometrial cancer drug gets breakthrough therapy designation

Seven pharma companies form alliance to prepare for pandemics

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics.  The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The alliance creation is in support of the 100 Days Mission,…

Continue Reading Seven pharma companies form alliance to prepare for pandemics

Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market is Predicted to Surge at 5% CAGR Over the Next Decade, Reaching US$ 17.1 Billion by 2032 | FMI Study

Non-Hodgkin lymphoma, often known as Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market, is a rare cancer that primarily affects the lymphatic system. Both children and adults can develop ALCL, which is distinguished by the aberrant proliferation of large, anaplastic lymphocytes. Chemotherapy, radiation therapy, targeted therapy, and stem cell transplantation are…

Continue Reading Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market is Predicted to Surge at 5% CAGR Over the Next Decade, Reaching US$ 17.1 Billion by 2032 | FMI Study

Anaplastic Large Cell Lymphoma Therapeutics Market Expected to Surpass US$ 17.1 Billion by 2032, Signifying Significant Growth Opportunities

PRESS RELEASE Published July 18, 2023 The Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market  is a rare type of non-Hodgkin lymphoma that primarily affects the lymphatic system. ALCL can occur in both children and adults, and it is characterized by the abnormal growth of large, anaplastic lymphocytes. Treatment options for…

Continue Reading Anaplastic Large Cell Lymphoma Therapeutics Market Expected to Surpass US$ 17.1 Billion by 2032, Signifying Significant Growth Opportunities

P62/SQSTM1 binds with claudin-2 to target for selective autophagy in stressed intestinal epithelium

McGuckin, M. A., Eri, R., Simms, L. A., Florin, T. H. & Radford-Smith, G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm. Bowel Dis. 15, 100–113 (2009). Article  PubMed  Google Scholar  Ahmad, R., Sorrell, M. F., Batra, S. K., Dhawan, P. & Singh, A. B. Gut permeability and mucosal inflammation:…

Continue Reading P62/SQSTM1 binds with claudin-2 to target for selective autophagy in stressed intestinal epithelium

Anaplastic Large Cell Lymphoma Alcl Therapeutics Market See Huge Growth for New Normal

The Anaplastic Large Cell Lymphoma Alcl Therapeutics Market research report provides all the information related to the industry. It gives the market’s outlook by giving authentic data to its client which helps to make essential decisions.  It gives an overview of the market which includes its definition, applications and developments,…

Continue Reading Anaplastic Large Cell Lymphoma Alcl Therapeutics Market See Huge Growth for New Normal

Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges | Military Medical Research

Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987;169(12):5429–33. Article  CAS  PubMed  PubMed Central  Google Scholar  Bhaya D, Davison M, Barrangou R. CRISPR-Cas systems in…

Continue Reading Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges | Military Medical Research

Recombinant ADAMTS13 Appears to Reduce TTP Events in Congenital Thrombotic Thrombocytopenic Purpura

In patients with congenital thrombotic thrombocytopenic purpura (TTP), there were no acute TTP events in a preplanned interim analysis of a phase 3 study evaluating the use of recombinant ADAMTS13 (rADAMTS13) prophylaxis. Study findings were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress by Marie Scully,…

Continue Reading Recombinant ADAMTS13 Appears to Reduce TTP Events in Congenital Thrombotic Thrombocytopenic Purpura

Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche’s OCREVUS with Halozyme’s ENHANZE Drug Delivery Technology in Patients with Multiple Sclerosis

SAN DIEGO – Halozyme Therapeutics, Inc. (NASDAQ: HALO) (‘Halozyme‘) today announced that Roche’s Phase 3 OCARINA II trial evaluating OCREVUS with ENHANZE as a twice a year 10-minute subcutaneous (SC) injection, met its primary and secondary endpoints in patients with relapsing forms of multiple sclerosis (MS) or primary progressive MS…

Continue Reading Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche’s OCREVUS with Halozyme’s ENHANZE Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Therapeutics (HALO) Reports Positive Data from Phase 3 OCARINA II Trial Evaluating Roche’s OCREVUS with ENHANZE

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme“) today announced that Roche’s Phase 3 OCARINA II trial evaluating OCREVUS® (ocrelizumab) with ENHANZE® as a twice a year 10-minute subcutaneous (SC) injection, met its primary and secondary endpoints in patients with relapsing forms of multiple sclerosis (MS) or primary progressive MS (RMS or…

Continue Reading Halozyme Therapeutics (HALO) Reports Positive Data from Phase 3 OCARINA II Trial Evaluating Roche’s OCREVUS with ENHANZE

Takeda Redacts Dengue Vaccine Application After FDA Requests More Data

Yesterday, Takeda Pharmaceutical Co. announced the withdrawal of a Biologics License Application (BLA) for its dengue vaccine candidate, TAK-003. Takeda opted to voluntarily rescind the application, reportedly after the US Food and Drug Administration (FDA) requested additional data not included in the phase 3 TIDES trial for TAK-003. The FDA’s…

Continue Reading Takeda Redacts Dengue Vaccine Application After FDA Requests More Data

PARP inhibitors: enhancing efficacy through rational combinations

Bai P. Biology of poly(ADP-Ribose) polymerases: the factotums of cell maintenance. Mol Cell. 2015;58:947–58. Article  CAS  PubMed  Google Scholar  Ray U, Raghavan SC. Understanding the DNA double-strand break repair and its therapeutic implications. DNA Repair. 2021;106:103177. Article  CAS  PubMed  Google Scholar  Wright WD, Shah SS, Heyer WD. Homologous recombination and…

Continue Reading PARP inhibitors: enhancing efficacy through rational combinations

Enrichment and characterization of a nitric oxide-reducing microbial community in a continuous bioreactor

Crutzen, P. J. The influence of nitrogen oxides on the atmospheric ozone content. Q. J. R. Meteorol. Soc. 96, 320–325 (1970). Article  Google Scholar  Johnston, H. Reduction of stratospheric ozone by nitrogen oxide catalysts from supersonic transport exhaust. Science 173, 517–522 (1971). Article  CAS  PubMed  Google Scholar  Hughes, M. N….

Continue Reading Enrichment and characterization of a nitric oxide-reducing microbial community in a continuous bioreactor

Thrombotic Microangiopathy Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 15+ Companies are working to improve the Treatment of Space

PRESS RELEASE Published July 7, 2023 (Albany, United States) As per DelveInsight’s assessment, globally, the Thrombotic Microangiopathy pipeline constitutes 15+ key companies continuously working towards developing 15+ Thrombotic Microangiopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.   In the Thrombotic…

Continue Reading Thrombotic Microangiopathy Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 15+ Companies are working to improve the Treatment of Space

J&J Plans Phase 3 Trial to Keep Pace in the Chase for Oral Psoriasis Drugs

Plaque psoriasis is already treatable with injectable biologic drugs, including two from Johnson & Johnson. Drugmakers are making headway with alternatives that offer efficacy comparable to biologics, but in pill formulations. J&J has one such drug in its pipeline and it now has mid-stage data that are keeping it in…

Continue Reading J&J Plans Phase 3 Trial to Keep Pace in the Chase for Oral Psoriasis Drugs

The Top 25 Healthcare Technology Leaders of 2023 for Connecticut

The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of Connecticut for 2023. There is no shortage of reasons for why Connecticut has a flourishing healthcare sector these days. The Nutmeg State, while small, boasts a high concentration of top-ranked hospitals and medical centers, renowned…

Continue Reading The Top 25 Healthcare Technology Leaders of 2023 for Connecticut